Healthy, smiling middle-aged man happy to be able to address his liver or cardiometabolic disease. Healthy, smiling middle-aged man happy to be able to address his liver or cardiometabolic disease.

Working to Address Liver and Cardiometabolic Diseases
with Growing Needs

We are a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. We are driven to help change the dynamic for patients, and through our experience, know that science is key to breaking this cycle of suboptimal treatments.

Our lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). We believe that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as NASH and SHTG.

Leadership

Our leadership team is built to tackle the many nuanced and multi-faceted needs of patients with liver and cardiometabolic diseases. We are well equipped to design and execute clinical development programs, and having created and led fully commercialized companies, we have the expertise to bring this potential new therapy to patients efficiently.

Rohan Palekar Chief Executive Officer
Rohan Palekar
Chief Executive Officer
Hank Mansbach, MD Chief Medical Officer
Hank Mansbach, MD
Chief Medical Officer
Quoc Le-Nguyen Chief Technical Operations Officer and Head of Quality
Quoc Le-Nguyen
Chief Technical Operations Officer and Head of Quality
Ryan Martins Chief Financial Officer
Ryan Martins
Chief Financial Officer
Melissa Abel Senior Vice President, Commercial Strategy
Melissa Abel
Senior Vice President, Commercial Strategy
Yun Bai, PhD Vice President, Head of Chemistry, Manufacturing and Controls (CMC)
Yun Bai, PhD
Vice President, Head of Chemistry, Manufacturing and Controls (CMC)
Michael Baldwin Vice President, Head of Quality
Michael Baldwin
Vice President, Head of Quality
Annie Chang Vice President, Investor Relations and Corporate Communications
Annie Chang
Vice President, Investor Relations and Corporate Communications
Jyoti Chauhan Vice President, Regulatory Affairs
Jyoti Chauhan
Vice President, Regulatory Affairs
Greg Gaich, MD Vice President, Clinical Development
Greg Gaich, MD
Vice President, Clinical Development
Amanda Kurihara Vice President, People & Culture
Amanda Kurihara
Vice President, People & Culture
Shiva Natarajan, CPA Senior Vice President, Finance & Principal Accounting Officer
Shiva Natarajan, CPA
Senior Vice President, Finance & Principal Accounting Officer
Paul Shin Senior Vice President, Research & Development Operations
Paul Shin
Senior Vice President, Research & Development Operations
Wenyan Wang, PhD Vice President, Clinical Development
Wenyan Wang, PhD
Vice President, Clinical Development

Board of Directors

Steven Altschuler, MD (Chairman)
Managing Director, Ziff Capital Partners
E. Morrey Atkinson, PhD
Executive Vice President and Chief Technical Operations Officer, Vertex Pharmaceuticals
Derek DiRocco, PhD
Partner, RA Capital Management
Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Kathy LaPorte
Rohan Palekar
CEO
Lota Zoth, CPA